BeiGene (BGNE) said late Thursday it has signed a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology for its experimental cancer therapy, SYH2039.
Under the terms of the deal, the company said it has an exclusive worldwide license to develop, manufacture and commercialize SYH2039.
CSPC will receive $150 million in upfront, time-based payments, potential milestone payments and tiered royalties.
The company said its experimental drug, BGB-58067, is expected to enter clinical trials by the end of the year and aims to avoid the hematological toxicity associated with first-generation PRMT5 inhibitors.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。